fig2
From: Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance
Figure 2. Glycolysis pathways in immune cells and their role in mediating drug resistance in GI cancers. This figure illustrates the critical metabolic pathways in MDSCs, TAMs, and Tregs that contribute to drug resistance in gastrointestinal cancers. These immune cells undergo metabolic reprogramming, promoting an immunosuppressive TME that supports cancer progression and reduces the efficacy of therapies. MDSCs: Myeloid-derived suppressor cells; TAMs: tumor-associated macrophages; Tregs: regulatory T cells; TME: tumor microenvironment.
